Stora Enso tops profit forecast, eyes 'new opportunities' amid trade war
April 25 (Reuters) - Finnish forestry group Stora Enso's (STERV.HE), opens new tab first-quarter operating profit beat market expectations on Friday, even as it warned that market demand would remain subdued amid concerns triggered by U.S. President Donald Trump's tariffs.
CEO Hans Sohlström said the direct impact at current tariff rates was limited, as Stora's direct sales to the U.S. accounted for just below 3% of group sales in 2024.
Local peer UPM (UPM.HE), opens new tab on Thursday also warned of an indirect tariff hit while saying the direct impact should be limited, despite its much bigger exposure to the United States.
Sohlström underscored that in addition to the risks, there were also opportunities arising from tariffs to develop Stora's sales into new markets, without specifying which regions he was referring to.
"The key here is ... to reposition, but also to renegotiate prices in the U.S. to compensate for tariffs in the U.S., but at the same time also to grasp new opportunities in new markets," he told Reuters in an interview.
The company's adjusted operating profit, or earnings before interest and taxes, rose to 175 million euros ($198.42 million)in the first quarter, trouncing analysts' 124.9 million euro forecast in a poll, opens new tab by Vara Research.
Its shares were up 1% at 0905 GMT, while UPM (UPM.HE), opens new tab fell 1%.
"The clearest outperformance against our forecasts came from Packaging Materials, Packaging Solutions and Wood Products in terms of turnover," Inderes analyst Antti Viljakainen said in a research note.
Stora also said it expected the ramp-up of its new packaging board line in Oulu, Finland to have a negative impact of about 100 million euros on its annual adjusted operating profit, and forecast capital expenditures of 730-790 million euros for 2025.
($1 = 0.8820 euros)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
44 minutes ago
- Daily Mail
NHS 'faces hike in drugs prices' as part of government's trade deal with Trump as US president seeks to help Big Pharma
The NHS could see billions added to its annual drugs bill under the trade deal done by Keir Starmer with Donald Trump 's America. The president wants foreign countries to pay more for drugs made in the US to help Big Pharma firms make more money abroad. The health service in England currently uses a drug-pricing scheme that sees drug-makers discount the price of medicine sold in bulk to avoid it busting a £20billion cap. But manufacturers have claimed the system is not viable and risks investment in the UK because it is more expensive than the schemes used by other countries. They pay back almost a quarter of their UK sales to the Government in rebates to avoid busting the cap, far more than the 15 per cent estimated and way above the average 5.7 per cent rebate in France, 7 per cent in Germany and 9 per cent in Ireland. The deal done at the start of May promised the sector 'significantly preferential treatment', with ministers vowing 'to improve the overall environment for pharmaceutical companies operating in the UK'. A White House source told the Telegraph it expected the NHS to start paying more to improve the balance sheets of American firms. Last week the CEO of Pfizer accused the UK and other European nations of 'free-riding all these years' on the back of US-based investment in pharmaceuticals. Albert Bourla told a conference that given US pressure on European countries to pay more, prices there could increase. He suggested the Trump administration should treat the sector like Nato defence spending and demand US allies pay more of their GDP into it. The US is also demanding the UK use fewer cheaper drugs from China, the Telegraph claimed. The President threatened to slap a 25 per cent tariff on UK pharmaceuticals entering the US, which last year totalled £6.6 billion. He also issued an executive order last month directing drugmakers to lower the prices of their medicines to align with what other countries pay. Health Secretary Wes Streeting is reviewing the rebate, which is likely to be wrapped in with ongoing US tariff talks, sources add. The UK spends a smaller share of its overall healthcare costs on medicines than any comparable country, according to the Association of the British Pharmaceutical Industry (ABPI), whose members includeUS drugs giants such as Pfizer, Bristol Myers Squibb, Amgen, Johnson & Johnson, Merck and Biogen.
The Independent
an hour ago
- The Independent
The five big questions that will dominate the G7
World leaders are gathered in Canada for a G7 summit set to be dominated by intense talks about the escalating conflict in the Middle East. With missiles being fired back and forth between Israel and Iran, Sir Keir Starmer, Donald Trump and others are in Kananaskis, Alberta until Tuesday. But while the summit has been overshadowed by rising tensions elsewhere, there are still a series of thorny issues for the G7 leaders to discuss. The Independent looks at the five big questions that will dominate the agenda at the summit. Trump v Carney A focal point of the whole summit will be the relationship between Mr Trump and his host, Canadian prime minister Mark Carney. The former Bank of England boss won April's general election riding a wave of anti-Trump sentiment across the country, following the US president's threats to turn Canada into America's 51st state. But, as host, it will fall to Mr Carney to build bridges between Mr Trump and the rest of the G7. They are scheduled for a meeting on Monday morning, with Mr Carney hoping to strike a trade and security deal with Mr Trump and exempt the country from damaging tariffs on steel, aluminium and cars. Mr Carney has a mammoth task on his hands to keep Mr Trump onside. The last time Canada hosted the G7 in 2018, Mr Trump lashed out at former PM Justin Trudeau and left without signing an agreed joint statement. Trump tariffs Meanwhile Mr Trump's relations are not just strained with Canada. All of the G7 leaders will want to quiz the US president on his future tariff plans and seek carve outs for their own countries from the damaging levies. His 'Liberation Day' measures are still on hold after the US International Trade court struck them down. But with the White House plotting ways to reimplement the universal tariffs, leaders at the G7 will be keen to push towards exemptions in the future. The World Bank has sharply downgraded its global economic outlook over Mr Trump's use of tariffs - blaming a 'substantial rise in trade barriers'. Russia and Ukraine Mr Trump campaigned on the promise he would end Russia's war in Ukraine within 24 hours of being re-elected. Six months on, negotiations over a peace deal between Vladimir Putin and Volodymyr Zelensky have stalled. G7 leaders will be piling pressure on Mr Trump to back tougher sanctions against Putin and his supporters. Sir Keir especially will be seeking assurances from Mr Trump that he will provide support to his so-called coalition of the willing, a peacekeeping force to be sent to Ukraine in the event of a permanent ceasefire. But, in a sign of the challenge they face, the US President recently suggested it might be better to let Ukraine and Russia 'fight for a while' in a sign of his waning interest in ending the three-year conflict. The environment Going into the summit, Canada wanted to talk about climate change and the environment, having suffered its worst wildfire season on record in 2023. Officials stressed that it was on the agenda for the summit, with the country hoping to focus world leaders on the growing global forest fire threat. Israel-Iran crisis But top of the agenda will be the unfolding crisis in the Middle East. Tensions between Iran and Israel are high and both sides are threatening escalation, while world leaders around the globe are calling for peace. Mr Trump said it is'possible' America could get involved in the conflict, which would present a challenge to allies who would then be expected to get involved as well. The crisis threatens to close the crucial Strait of Hormuz shipping lane, which would deal a severe blow to global trade.
Reuters
an hour ago
- Reuters
India cenbank seeks market views on aligning call money rate with repo, sources say
MUMBAI, June 16 (Reuters) - The Reserve Bank of India has sought feedback from large market participants on aligning the overnight interbank call money rate more closely with the policy repo rate, five treasury officials aware of the discussions told Reuters on Monday. The move follows a Reuters report last week that said the RBI wants the overnight call rate to broadly align with the policy repo rate and is considering steps to ensure that happens. The policy rate currently stands at 5.50%, while the overnight call rate averages 5.30% and the TREPS rate hovers near 5.20%. The overnight call rate and TREPS rate have averaged below the policy rate since April. A persistent gap between the RBI's operative rate and the policy rate typically signals that banks are accessing cheaper funding than what the central bank is comfortable with. The RBI spoke with large treasury officials on Friday to review liquidity conditions and understand why the overnight call rate — the operative policy target — has been persistently trailing the repo rate, two of the sources said. None of the sources wanted to be named because they are not authorised to speak to the media. The RBI did not immediately reply to a Reuters email seeking comment. The central bank is also keen to understand why treasury bill yields have spiked in the last week, the two sources added. The yield on 364-day notes was sharply higher than estimates last Wednesday. "The motive seemed to be to sensitise the market that a variable rate reverse repo auction would be in the offing," a senior official at a state-run bank said. The source had added that the RBI could start conducting variable rate reverse repo auctions to suck out surplus liquidity as and when required. The weighted average overnight call rate has remained well below the RBI's key repo rate and closer to the policy corridor's floor, the Standing Deposit Facility rate, for the past few weeks. On June 6, the RBI slashed its key policy rate by 50 basis points, but changed its stance to neutral, indicating limited room for further cuts. The RBI also announced a reduction in banks' cash reserve ratio by 100 basis points September onwards. The central bank also stopped conducting daily fund infusion through variable rate repo since June 11, which market took as an indication that the RBI may move towards VRRR soon. Market participants have requested that the RBI avoid shocks in liquidity management which would help avoid volatility in short-term rates, another treasury official said. "Given that the focus of monetary policy is on enhancing transmission, the expectation channel is equally important. Hence, it would be better to move overnight rates towards repo rate after some time, allowing transmission to gain pace," said Gaura Sen Gupta, chief economist with IDFC First Bank.
